HITI
High Tide Inc.
HITI has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over HITI overall, supported by stronger fundamentals and stronger modeled upside.
HITI Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Weak |
HITI's revenue is currently strong, but its profitability, cash flow and balance sheet are under pressure.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HITI PE Valuation
HITI has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
HITI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for HITI, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
HITI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.27 | -$0.22 |
| Q2 2026 | -$0.35 | -$0.30 |
| Q1 2026 | -$0.38 | -$0.36 |
| Q4 2025 | -$0.41 | -$0.41 |
| Q4 2024 | -$0.00 | +$0.37 |
| Q4 2023 | -$0.37 | +$0.38 |
| Q3 2023 | -$0.60 | -$0.31 |
| Q2 2023 | -$0.60 | -$0.32 |
HITI is still losing money, but far less than before: $0.27 per share over the past year, against $1.38 at its worst in early 2020.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over HITI on earnings quality, reporting a profit while its opponent remains loss making.
HITI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $141.3M | +34% |
| Q2 2026 | $126.1M | +30% |
| Q1 2026 | $125.6M | +25% |
| Q4 2025 | $115.3M | +19% |
| Q3 2025 | $105.2M | +14% |
| Q2 2025 | $96.9M | +11% |
| Q1 2025 | $100.2M | +11% |
| Q4 2024 | $97.2M | +8.8% |
HITI's revenue has grown year over year every quarter since early 2021: $141M last quarter, up 34% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 4.3% | +1.8 points |
| Q2 2026 | 4.5% | +3.8 points |
| Q1 2026 | 2.3% | +2.3 points |
| Q4 2025 | -12% | -9.6 points |
| Q3 2025 | 2.5% | +0.2 points |
| Q2 2025 | 0.7% | -0.9 points |
| Q1 2025 | 0.1% | -2.1 points |
| Q4 2024 | -2% | N/A |
HITI has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over HITI on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
HITI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.5M | +10% |
| Q2 2026 | $1.6M | -59% |
| Q1 2026 | $2.2M | +$3.7M |
| Q4 2025 | $812.7K | -85% |
| Q3 2025 | $5.9M | +206% |
| Q2 2025 | $4M | -46% |
| Q1 2025 | -$1.4M | -143% |
| Q4 2024 | $5.4M | +2.4% |
HITI still generates free cash flow, though less than at its 2024 peak: $11M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over HITI on cash flow, with more consistent year-over-year improvement.
HITI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +7.6% | +6.7M shares |
| 1 year | +6.8% | +6M shares |
| 3 years | +26% | +19.6M shares |
| 5 years | +96% | +46.2M shares |
| Available history | +672% | +82.3M shares |
HITI has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
HITI hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HITI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 17.4x | High |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 1.0x | Healthy |
| Q1 2025 | 1.1x | Healthy |
| Q4 2024 | 0.8x | Very low |
| Q3 2022 | 5.6x | High |
| Q2 2022 | 5.1x | High |
| Q1 2022 | 7.5x | High |
HITI's net debt is about 17 years of its operating earnings (EBITDA), up from less than a year a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over HITI on leverage, with a lower net debt burden relative to earnings.
HITI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.0 | Neutral |
| Stochastic | 59.7 | Neutral |
HITI's weekly RSI is 50 (neutral) and its Stochastic is 60 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
HITI PE vs Healthcare Sector
HITI has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HITI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.61 | 4.2% below |
| 20 week MA | $2.46 | 1.6% above |
| 50 week MA | $2.46 | 1.6% above |
| 100 week MA | $2.59 | 3.5% below |
| 200 week MA | $2.20 | 14% above |
HITI's trend is mixed: it's above three of its five weekly moving averages, and 14% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over HITI on trend strength, trading above more of its moving averages.
HITI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $3.15 | $4.70 | +49% |
| 2022 | $4.70 | $1.43 | -70% |
| 2023 | $1.43 | $1.63 | +14% |
| 2024 | $1.63 | $3.05 | +87% |
| 2025 | $3.05 | $2.78 | -8.9% |
| 2026 YTD | $2.78 | $2.50 | -10% |
HITI has finished higher in three of the last five years. It's down 10% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over HITI on returns for 2026, with the stronger performance.